What is the future of Health Tech? Boston is the birthplace of some of the sector’s most impactful ideas, but how do the local early stage startups stack up against their counterparts across the globe?
Join us at OBERON for Pitch Night 2019, where 10 of Switzerland’s most promising young Health Tech startups will pitch their ideas alongside their counterparts from North America, including some of the Boston area’s favorite early Life Sciences startups.
This isn’t your standard pitch event.
20 startups. 1 minute to pitch. 2 winners - a jury selection and an audience favorite. Join us for a drink, a live jazz band and fast-paced competition. This is your chance to mingle with the local and international Health Tech ecosystem, get a glimpse of the latest Health Tech innovations and meet the swissnex Boston team.
Event presented by swissnex Boston and VentureLab with support from Hansjörg Wyss.
Program support provided by the following partners:
5:30 pm Arrival and networking
6:00 pm Program begins
6:20 pm Round 1: 20 one-minute pitches
7:15 pm Round 2: Round 1 winners answer the jury’s secret question
7:35 pm Public prize and jury prize awarded
8:00 pm Networking reception
Meet the startups
4D Lifetec AG | Arne-Christian Faisst
Unreliable tumor detection leads to unspecific therapy. 4D Lifetec is developing a fast, cost-effective and more precise assay to help identify lung and prostate cancers earlier. The company's liquid biopsy assay device is currently undergoing clinical testing.
Juvabis AG | Sven Hobbie | ETH Zurich
Drug-resistant bacteria are a threat to modern medicine. Juvabis, a joint startup of the ETH and University of Zurich, is preparing its new, small-molecule antibiotic for clinical trials in humans this year.
Medyria AG | Mauro Sette
Aneurysm repairs prevent bloated blood vessels from bursting dangerously. These vital interventions have harmful side-effects. Medyria's sensor uses blood flow velocity to measure a catheter location, helping reduce the risk of spinal injuries during surgery.
Pattern BioSciences AG | Yaakov Benenson | ETH Zurich
Developing sophisticated drugs to increase the chance of effective cancer treatment by targeting combinations of molecules, instead of single molecules. The company’s lead candidate to treat liver cancer is in preclinical development.
Positrigo AG | Jannis Fischer | ETH Zurich
Alzheimer's affects 50 million people worldwide. PET scanners can reveal proteins linked to the disease 20 years before the cognitive effects are noticeable. Positrigo's scanner will reduce the cost tenfold, making precautionary scanning viable.
Resistell AG | Danuta Cichocka | EPF Lausanne
Developed a diagnostic device to identify the best antibiotic to treat a particular infection between 10- and 100-times faster. This reduces the cost of hospital infections and slows antibiotic resistance, by helping treat infection with the correct antibiotic first time.
Scailyte AG | Peter Nestorov | University of Basel
Single-cell analysis is tipped to become a key tool in biomedical research. Currently the industry can’t extract all the data from highly complex single-cells. Scailyte is developing AI-based data analytics to boost research, drug discovery and precision diagnostics.
Synendos Therapeutics | Andrea Chicca | University of Bern
Developing drugs to treat post-traumatic stress disorder and other neuropsychiatric disorders by modulating a new target. Restores natural brain functioning by inhibiting endocannabinoid transport across cell membranes. An effective, breakthrough therapy.
TOLREMO Therapeutics AG | Stefanie Flückiger-Mangual | ETH Zurich
Cancer drugs often lose their effectiveness over time, which makes tumors that require continuing treatment difficult to manage. TOLREMO’s new molecules eradicate drug resistant cancer cells at the start of a therapy, and can be combined with existing drugs.
Volumina Medical SA | Amélie Béduer | EPF Lausanne
Developed an injectable scaffolding that helps the body to rebuild after surgery. Enables the natural reconstruction of soft tissues, as well as glandular, connective and supporting tissues. First product will serve women’s reconstructive therapy after a mastectomy.
From North America:
Akanocure | Sherine Abdelmawla
Second generation small molecules (SGSM) have the affinities and protein-protein interactions of macromolecules while retaining the high tumor permeability of small molecules. Akanocure’s “Chiral Carbon Catalog” synthesis platform creates SGSM analogues that are scalable and less expensive, starting with a lead candidate for advanced ovarian cancer.
Limax Biosciences | Ben Freedman | Harvard iLabs
Strong, stretchy and flexible hydrogel adhesive platform to seal wounds and promote healing throughout the body. The technology is based on bio-inspired materials.
Myofinity Biosciences | Richard Horgan | Boston Children’s Hospital
Duchenne Muscular Dystrophy is a progressive genetic disease leading to muscle weakness and muscle loss. Myofinity’s lead technology is a recombinant human protein that has been shown to aid in the membrane resealing of disease model animals.
Kernal Biologics | Yusuf Erkul
Developing fully onco-selective and oncolytic messenger RNA therapies via deep learning algorithms, transcriptomics and proteomics datasets from cancer samples. Lead candidate Onco-333 is targeted toward AML.
Axonis | Joanna Stanicka
There are no effective therapies that can restore movement in paralyzed patients after spinal cord injury. Axonis is developing iPTEN, a breakthrough neuroregenerative gene therapy, which inhibits the PTEN protein. iPTEN treatment induces the severed nerve connections between the brain and spinal cord to regrow leading to function recovery in animal models. Through clinical trials, Axonis aims to bring this groundbreaking therapy to those in need.
Versatope | Christopher Locher
Versatope Therapeutics is developing a transformative and highly effective platform for improving cancer immunotherapy and vaccines with extracellular vesicles. They use nano-sized exosome-like vesicles derived from probiotic cell membranes and licensed from Cornell University.
Loro | Johae Song
Based in Boston, MA, Loro, co is an early-stage startup that is developing a smart companion robot for a wheelchair user named “Loro.” Loro empowers its users with increased independence and connectedness by enhancing their vision, communication, and safety.
Visionairy Health | Mortitz Graule
Visionairy Health is developing the first automated screening platform for radiological images that leverages a proprietary dataset and deep learning to differentiate between normal and abnormal chest x-rays.
Iterative Scopes | Jonathan Ng
Colorectal cancer is the second leading cause of cancer-related deaths in the United States, despite being preventable by early detection. Iterative Scopes’ software provides real-time lesion detection and diagnostic support to doctors during and after endoscopic examination.
ActiPulse | Adrien Chatillon
Actipulse Neuroscience® is a neuro-tech company specialized in the clinical research, engineering and manufacturing of non-invasive technologies to treat Parkinson’s Disease and dementia. Their patent-pending devices use a proprietary neuromodulation technology that has been clinically proven to revert motor dysfunction, restore memory traits and decrease anxiety.
Vice President, MassVentures
Jason joined MassVentures in 2018 as a Vice President. Before working at MassVentures, he was the Vice President of Media at Ovia Health, a Boston-based women’s digital health company that helps women navigate their fertility, pregnancy and parenting journey with the goal of improving outcomes. Jason has also held positions at Launch Capital, Attivio, & LogMeIn.
Alex Harding, MD, MBA
Associate, Atlas Venture
Alex is an Associate at Atlas Venture and focuses on forming companies based on breakthrough science with the potential to transform therapies for patients with the most serious and intractable illnesses. He is also a practicing Physician who sees patients at Massachusetts General Hospital. Alex founded a non-profit company called Water Ecuador, which provides clean and affordable drinking water to thousands of people in a low-income, rural region in Ecuador.
Associate Principal, Schooner Capital
Alexandra is an Associate Principal focused on venture and growth stage investments. She currently serves as a Director at Remedy Plan Therapeutics. Prior to Schooner, she worked as a process engineer for MIT spin-out start-up, 1366 Technologies, analyzed automobile manufacturing practices for the CTO at Tesla Motors, and consulted for various early stage tech companies. Alex holds a BS in Materials Science & Engineering from MIT and an MBA from Stanford University.
Partner, Material Impact
Elyse is a Partner for Material Impact, where she directs all marketing activities for the firm and supports the brand building and commercial efforts of Material Impact entrepreneurs. She was named Forbes “30 Under 30” in Marketing & Advertising, a “Future Industry Leader” by the Sports & Fitness Industry Association, and a "Rising Star” by the Healthcare Businesswomen's Association. Prior to joining Material Impact, Elyse served as Vice President of Marketing for Lose It! and directed Marketing for MC10. She has also held strategic marketing positions at healthcare management consulting firms, Vynamic, and Merrill Lynch.